AIDS dementia complex: Incidence, clinical profile and impact of zidovudine treatment

European Journal of Neurology

Volumn 3, Issue 3, 1996, Pages 191-197

  Sanchez Portocarrero J ^a   Jimenez Escrig A ^b   Perez Cecilia E ^a   Ayuso Mateos, J L ^c   Roca, V ^a   Ruiz Yague, M ^a   Barquero, M ^a   Ramirez C ^a   Varela De Seijas, E ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

AIDS; AIDS dementia complex; Human immunodeficiency virus; Zidovudine; 2 microglobuin

Indexed keywords

ANTIVIRUS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; HEMOGLOBIN; IMMUNOGLOBULIN A ANTIBODY; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; DEMENTIA; DISEASE COURSE; FEMALE; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; TOXOPLASMOSIS;

EID: 0029886587     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1996.tb00422.x     Document Type: Article

References (45)

1. d'Arminio Monforte A, Vago L, Lazzarin A, Boldorini R, Bini T, Guzzetti S, Antinori S, Moroni M and Costanzi G (1992) AIDS-deining diseases in 250 HIV-infected patients; a comparative study clinical and autopsy diagnoses. AIDS, 6, 1159-1164.
2. Brew BJ (1993) HIV-1-Related neurological disease. Journal of Acquired Immune Deficiency Syndromes, 6(suppl. 1), S10-S15.
3. Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK and Price RW (1990) Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Annals of Neurology, 28, 556-560.
4. Brew BJ, Bhalla RB, Paul M, Sidtis JJ, Keilp JJ, Sadler AE, Gallardo H, McArthur JC, Schwartz MK and Price RW (1992) Cerebrospinal fluid β2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS, 6, 461-465.
5. Burger DM, Kraaijeveld CL, Meenhorst PL, Mulder JW, Koks CHW, Bult A and Beijnen JH (1993) Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV AIDS, 7, 1581-1587.
6. Centers for Disease Control (1987) Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbidity and Mortality Weekly Report, 36(suppl), 1S-15S.
7. Davey RT and Lane HC (1990) Laboratory methods in the diagnosis and prognostic staging of infection with human immunodeficiency virus type 1. Reviews of Infectious Diseases, 12, 912-930.
8. de Gans J, Lange JMA, Derix MMA, de Wolf F, Eeftinck Schattenkerk JK, Danner SA, Ongerboer de Visser BW, Cload P and Goudsmit J (1988) Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS, 2, 37-40.
9. Glass JD, Wesselingh SL, Selnes OA and McArthur JC (1993) Clinical-neuropathologic correlation in HIV-associated dementia. Neurology, 43, 2230-2237.
10. Grant I, Atkinson JH, Hesselink JR, Kennedy CJ, Richman DD, Spector SA and McCutchan JA (1987) Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Annals of Internal Medicine, 107, 828-836.
11. Gray F, Geny C, Dournon E, Fenelon G, Lionnet F and Gherardi R (1991) Neuropathological evidence that zidovudine reduces incidence of HIV infection of brain. Lancet, 337, 852-853.
12. Gulevich SJ, McCutchan JA, Thal LJ, Kirson D, Durand D, Wallace M, Mehta P and Grant I (1993) Effect of antiretroviral therapy on the cerebrospinal fluid of patients seropositive for the human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes, 6, 1002-1007.
13. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, Mouradian MM, Sadler AE, Keilp J, Rubinow D and Markey SP (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Annals of Neurology, 29, 202-209.
14. Janssen RS, Saykin AJ, Kaplan JE, Spira TJ, Pinsky PF, Sprehn GC, Hoffman JC, Mayer WB Jr and Schonberger LB (1988) Neurological complications of human immunodeficiency virus infection in patients with lymphadenopathy syndrome. Annals of Neurology, 23, 49-55.
15. Janssen RS, Cornblath DR, Epstein LG, Foa RP, McArthur JC and Price RW (1991) Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology, 41, 778-785.
16. Janssen RS, Nwanyanwu OC, Selik RM and Stehr-Green JK (1992) Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology, 42, 1472-1476.
17. Koppel BS, Wormser GP, Tuchman AJ, Maayan S, Hewlett D and Daras M (1985) Central nervous system involvement in patients with acquired immune deficiency syndrome (AIDS). Acta Neurologica Scandinavica, 71, 337-353.
18. Levy RM, Bredesen DE and Rosenblum ML (1985) Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. Journal of Neurosurgery, 62, 475-495.
19. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, Yeboue K, Hondé M, Diomande M, Giordano C, Doorly R, Brattegaard K, Kestens L, Smithwick R, Kadio A, Ezani N, Yapi A and De Cock KM (1993) The mortality and pathology of HIV infection in a West African city. AIDS, 7, 1569-1579.
20. Maj M, Satz P, Janssen R, Zauding M, Starace F, D'Elia L, Sughondhabirom B, Mussa M, Naber D, Ndetei D, Schulte G and Sartorius N (1994) WHO neuropsychiatrie AIDS study, cross-sectional phase II. Archives of General Psychiatry, 51, 51-61.
21. Martínez-Martín P, Diez-Tejedor E and Grupo Colaborativo Multicéntrico (1989) Complicaciones neurológicas del SIDA. Panorámica según una encuesta hospitalaria multicéntrica. Archivos de Neurobiologia (Madrid), 52(suppl.)1, 23-29.
22. Mayeux R, Stern Y, Tang M-X, Todak G, Marder K, Sano M, Richards M, Stein Z, Ehrhardt AA and Gorman JM (1993) Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology, 43, 176-182.
23. McArthur JC, Nance-Sproson TE, Griffin DE, Hoover D, Selnes OA, Miller EN, Margolick JB, Cohen BA, Farzadegan H and Saah A (1992) The diagnostic utility of elevation in cerebrospinal fluid β2-microglobulin in HIV-1 dementia. Neurology, 42, 1707-1712.
24. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NMH, McArthur JH, Seines OA, Jacobson LP, Visscher BR, Concha M and Saah A (1993) Dementia in AIDS patients: incidence and risk factors. Neurology, 43, 2245-2252.
25. Moeller AA and Backmund HC (1990) Ventricle brain ratio in the clinical course of HIV infection. Acta Neurologica Scandinavica, 81, 512-515.
26. Mundinger A, Adam T, Ott D, Dinkel E, Beck A, Peter HH, Volk B and Schumacher M (1992) CT and MRI: prognostic tools in patients with AIDS and neurological deficits. Neuroradiology, 35, 75-78.
27. Navia BA and Price RW (1987) The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Archives of Neurology, 44, 65-69.
28. Navia BA, Jordan BD and Price RW (1986) The AIDS dementia complex: I. Clinical features. Annals of Neurology, 19, 517-524.
29. Petito CK (1993) What causes brain atrophy in human immunodeficiency virus infection? Annals of Neurology, 34, 128-129.
30. Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M, Broder S, Yarchoan R, Brunetti A, Maha M, Nusinoff-Lehrman S and Poplack DG (1988) Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. New England Journal of Medicine, 319, 889-896.
31. Portegies P, de Gans J, Lange JM, Derix MMA, Speelman H, Bakker M, Danner SA and Goudsmit J (1989) Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. British Medical Journal, 299, 819-821.
32. Portegies P, Enting RH, de Gans J, Algra PR, Derix MMA, Lange JMA and Goudsmit J (1993) Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS, 7, 669-675.
33. Price RW and Brew BJ (1988) The AIDS dementia complex. Journal of Infectious Diseases, 158, 1079-1083.
34. Reivang I, Froland SS, Karlsen NR and Lundervold AJ (1991) Only temporary improvement in impaired neuropsychological function in AIDS patients treated with zidovudine. AIDS, 5, 228-229.
35. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL and the AZT Collaborative Working Group (1988) Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine, 319, 1573-1578.
36. Seilhean D, Duyckaerts C, Vazeux R, Bolgert F, Brunet P, Katlama C, Gentilini M and Hauw J-J (1993) HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex. Neurology, 43, 1492-1499.
37. Sharer LR (1992) Pathology of HIV-1 infection of the central nervous system. A review. Journal of Neuropathology and Experimental Neurology, 51, 3-11.
38. Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Kieburtz K, Simpson D, Koch MA, Feinberg J, Dafni U and the AIDS Clinical Trials Goup (1993) Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Annals of Neurology, 33, 343-349.
39. Snider WD, Simpson DM, Nielsen S, Gold JWM, Metroka CE and Posner JB (1983) Neurological complications of acquired immunodeficiency syndrome: analysis of 50 patients. Annals of Neurology, 14, 403-418.
40. St Clair MH, Hartigan PM, Andrews JC, Vavro CL, Simberkoff MS, Hamilton JD and the VA Cooperative Study Group (1993) Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. Journal of Acquired Immune Deficiency Syndromes, 6, 891-897.
41. Tartaglione TA, Collier AC, Coombs RW, Opheim KE, Cummings DK, Mackay SR, Benedetti J and Corey L (1991) Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Archives of Neurology, 48, 695-699.
42. Tozzi V, Narciso P, Galgani S, Sette P, Balestra P, Gerace C, Pau FM, Pigorini F, Volpini V, Camporiondo MP, Giulianelli M and Visco G (1993) Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS, 7, 683-692.
43. Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P and Constanzi G (1993) Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. Journal of Acquired Immune Deficiency Syndromes, 6, 42-45.
44. Wainberg MA, Gu Z, Gao Q, Arts E, Geleziunas R, Bour S, Beaulieu R, Tsoukas C, Singer J and Montaner J (1993) Clinical correlates and molecular basis of HIV drug resistance. Journal of Acquired Immune Deficiency Syndromes, 6(Suppl.1), S36-S46.
45. Yarchoan R, Berg G, Brouwers P, Fischl MA, Spitzer AR, Wichman A, Grafman J, Thomas RV, Safai B, Brunetti A, Perno CF, Schmidt PJ, Larson SM, Myers CE and Broder S (1987) Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet, 1, 132-135.